Literature DB >> 19696181

Involvement of platelet coagulation and inflammation in the endothelium of Schlemm's canal.

Yukiko Watanabe1, Teruhiko Hamanaka, Tamiko Takemura, Akira Murakami.   

Abstract

PURPOSE: To investigate whether the endothelial cells of Schlemm's canal (ECSCs) are connected to lymphatic vessels or are involved in platelet coagulation and inflammation, by comparing them to lung tissue cells.
METHODS: Three normal eyes, trabeculectomy specimens of 6 early-onset primary open-angle glaucoma (POAG), 15 late-onset POAG, and 6 normal-tension glaucoma (NTG), and lung tissues from 10 normal autopsy cases were used. The specimens were processed for light microscopy of immunohistochemical staining. The antibodies used in this study were von Willebrand factor (vWF) and thrombomodulin for evaluating the platelet coagulation system, CD 34 as a marker for blood vessels, platelet/endothelial cell adhesion molecule (PECAM-1) and E-selectin for evaluating the involvement of inflammation, and D2-40 as a marker for lymphatic vessels.
RESULTS: Thrombomodulin, CD 34, PECAM-1 and E-selectin were detected in ECSCs, the endothelial cells of Sondermann's canal, and the endothelial cells of alveolar capillaries in the lung (EACL), whereas vWF was negative in those cells. Sondermann's canal was often found in compact juxtacanalicular tissue (JCT) in eyes with early-onset POAG. D2-40 was positive in the endothelial cells of lymphatic vessels in the lung (ELVL) and trabecular cells. In early-onset POAG, trabecular cells in JCT were mostly negative for D2-40.
CONCLUSIONS: ECSCs and EACLs are suggested to have developed specifically for their functions from the aspects of the anti-platelet coagulation system and may be involved in inflammation for leukocyte infiltration. D2-40 and thrombomodulin seem to be useful for evaluating morphologic abnormality in POAG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696181     DOI: 10.1167/iovs.08-3279

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Organogenesis and distribution of the ocular lymphatic vessels in the anterior eye.

Authors:  Yifan Wu; Young Jin Seong; Kin Li; Dongwon Choi; Eunkyung Park; George H Daghlian; Eunson Jung; Khoa Bui; Luping Zhao; Shrimika Madhavan; Saren Daghlian; Patill Daghlian; Desmond Chin; Il-Taeg Cho; Alex K Wong; Martin Heur; Sandy Zhang-Nunes; James C Tan; Masatsugu Ema; Tina T Wong; Alex S Huang; Young-Kwon Hong
Journal:  JCI Insight       Date:  2020-07-09

2.  Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis.

Authors:  Tavé van Zyl; Wenjun Yan; Alexi McAdams; Yi-Rong Peng; Karthik Shekhar; Aviv Regev; Dejan Juric; Joshua R Sanes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-27       Impact factor: 11.205

3.  Platelet Parameters and Their Relationships With the Thickness of the Retinal Nerve Fiber Layer and Ganglion Cell Complex in Primary Open-Angle Glaucoma.

Authors:  Yi Ma; Shengjie Li; Mingxi Shao; Wenjun Cao; Xinghuai Sun
Journal:  Front Neurol       Date:  2022-05-02       Impact factor: 4.086

4.  Association between Platelet Parameters and Glaucoma Severity in Primary Open-Angle Glaucoma.

Authors:  Yi Ma; Jianping Han; Shengjie Li; Aiping Zhang; Wenjun Cao; Xinghuai Sun
Journal:  J Ophthalmol       Date:  2019-05-09       Impact factor: 1.909

5.  Fourier-Domain Optical Coherence Tomographic Assessment of Changes in the Schlemm's Canal of Nonglaucomatous Subjects After Keratoplasty.

Authors:  Yujin Zhao; Yue Li; Jiaxu Hong; Qihua Le; Jianjiang Xu
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

6.  Schlemm's canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process.

Authors:  Krishnakumar Kizhatil; Margaret Ryan; Jeffrey K Marchant; Stephen Henrich; Simon W M John
Journal:  PLoS Biol       Date:  2014-07-22       Impact factor: 8.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.